Skip to main content
OncoTherapy Science, Inc. logo

OncoTherapy Science, Inc. — Investor Relations & Filings

Ticker · 4564 ISIN · JP3202150003 LEI · 529900CIAZCAIG781H52 T Professional, scientific and technical activities
Open in API
Filings indexed 71 across all filing types
Latest filing 2025-02-18 AGM Information
Country JP Japan
Listing T 4564

About OncoTherapy Science, Inc.

https://www.oncotherapy.co.jp/en/

OncoTherapy Science, Inc. is a biopharmaceutical company focused on the research and development of novel anti-cancer therapies. The company utilizes cancer-specific gene data and comprehensive cancer genome analysis to discover and develop molecular-targeted drugs, antibody drugs, cancer vaccines, and new immunotherapies. Its key technological focuses include liquid biopsy, neoantigen prediction, and T-cell receptor (TCR) repertoire analysis using next-generation sequencing. The company's primary objective is to develop highly effective cancer treatments with minimal adverse events and side effects for patients.

Recent filings

Filing Released Lang Actions
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director. Section 1 explicitly states the reason for filing: a resolution was passed at the Extraordinary General Meeting of Shareholders held on February 14, 2025, requiring submission under the Financial Instruments and Exchange Act. Section 2 details the resolution, which concerns a capital reduction (無償減資). Crucially, the document reports the results of a shareholder vote (賛成, 反対, 棄権) and confirms the resolution passed. This content—reporting the official results of a shareholder vote following a general meeting—aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not the AGM presentation (AGM-R), the full annual report (10-K), or a general earnings release (ER).
2025-02-18 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains Japanese characters and includes the title "第２四半期報告書" (Second Quarter Report) and references the period "自 2024年４月１日 至 2024年９月30日" (April 1, 2024, to September 30, 2024). It also mentions confirmation by the Representative Director regarding the appropriateness of the filing based on the Financial Instruments and Exchange Act. A comprehensive report for a period shorter than a year (like a semi-annual or quarterly report) corresponds to the Interim / Quarterly Report category (IR). Although it is a confirmation document related to the report, the core subject matter is the semi-annual financial reporting period, making IR the most appropriate classification over a general RPA or RNS, as it is a specific regulatory filing type related to interim financials.
2024-11-11 Japanese
半期報告書－第24期(2024/04/01－2025/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '第２四半期報告書' (Second Quarter Report) for OncoTherapy Science, Inc., covering the period from April 1, 2024, to September 30, 2024. It contains detailed financial statements, management analysis (MDA), and business status updates, which are characteristic of a formal interim/quarterly financial report. It is not a mere announcement (RPA) or a certification, as it contains substantive financial data and analysis. H1 2025
2024-11-11 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were made at the Annual General Meeting (AGM) held on June 25, 2024. Section 2 details the resolutions, specifically the election of directors and auditors, and provides the voting results (votes for, against, abstentions, and passing requirements). This content perfectly matches the definition of reporting the results of a shareholder vote following a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-06-28 Japanese
内部統制報告書－第23期(2023/04/01－2024/03/31)
Governance Information Classification · 100% confidence The document is explicitly titled "内部統制報告書" (Internal Control Report) in the header and throughout the text. It references the legal basis as Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法第24条の４の４第１項), which mandates the filing of an internal control report by listed companies in Japan. The content details the framework, scope, criteria (using March 31, 2024, as the cutoff date), and the conclusion that internal controls over financial reporting are effective. This directly corresponds to the definition of an Audit Report / Information (AR), as it deals with internal controls and assurance over financial reporting, distinct from the full Annual Report (10-K) or a simple Earnings Release (ER). Although 'AR' is defined as 'Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests', an Internal Control Report (which is a required component of the annual filing process in Japan, often filed separately or alongside the 10-K equivalent) fits best under this category as it is a formal report on the integrity of financial reporting controls.
2024-06-25 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document text contains Japanese characters and includes the phrase "有価証券報告書" (Yūka Shōken Hōkokusho), which translates to 'Securities Report' or 'Annual Securities Report'. It also explicitly mentions the submission date (2024年６月25日), the company name, and confirms that the content of the report for the fiscal year ending March 31, 2024, is appropriate according to the Financial Instruments and Exchange Act. This strongly indicates the document is related to the official annual filing. In the US context, the comprehensive annual report is the 10-K. While the Japanese term is broader, among the provided codes, '10-K' is the closest equivalent for a full, official annual financial report. However, the document structure provided (with sections like '【提出書類】 確認書' - Submission Document: Confirmation Letter) suggests this might be a certification or confirmation *accompanying* the main report, rather than the full report itself. Given the short length (588 chars) and the focus on confirmation ('確認書'), it aligns better with a regulatory confirmation or a cover document rather than the full '10-K' content. Since there is no specific code for a Japanese Annual Report Confirmation, and it is a core regulatory filing related to annual performance disclosure, '10-K' remains the most appropriate classification for the underlying report type being certified, assuming this is the certification attached to the main filing. Revisiting the definitions: '10-K' is defined as 'Official yearly report covering company activity and full financial performance.' This document is a confirmation *of* that report. If this were an announcement *about* the 10-K release, it would be RPA. Since it contains substantive confirmation details about the content of the annual filing, classifying it as the primary annual filing type (10-K) is the best fit, as it is intrinsically linked to the full annual disclosure. FY 2024
2024-06-25 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.